Enrolling by invitation
Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children 6 to 17 Years, With Heterozygous FH
NCT07102511
- Conditions
- Dyslipidemias, Familial Hypercholesterolemia - Heterozygous, Hypercholesterolemia, +4 more
- Locations
-
- Metabolic & Atherosclerosis Research Center Cincinnati, Ohio, United States
- Lipid Clinic Hadassah Medical Center Jerusalem, Israel
- New Zealand Clinical Research Christchurch, New Zealand
- The Lipid Clinic Oslo University Hospital Oslo, Norway